ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
ACIST Medical Systems, a Bracco company, has received FDA clearance and launched its ACIST Pro Diagnostic System in the U.S. The system is a variable-rate contrast management platform for image-guided cardiovascular procedures.
Bracco described ACIST Pro as the next generation of its CVi automated contrast delivery technology. CVi replaced manual injection with automated, real-time contrast delivery in cardiac catheterization laboratories, according to the company.
Clinical use of CVi has been associated with an average 45 mL reduction in contrast use, a 30% reduction in contrast-induced acute kidney injury, and an average of 5 minutes saved per case, Bracco said.
Product materials list real-time contrast tracking, customizable target limits, prominent contrast utilization display, and smart detection of disposables among the platform’s features.
Setup time is 33% shorter than CVi, according to an ACIST product brochure. The company cited a faster filling syringe, new peri-pump design, flush bag, and user interface as contributors to reduced setup time.
Japan was the first launch market in 2025. Select European markets followed after the system received CE mark approval under the European Medical Device Regulation in February 2026.
ACIST is headquartered in Eden Prairie, MN. The company develops interventional and diagnostic technologies, including contrast imaging systems for cardiovascular angiography and radiology imaging.
Company:ACIST
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.
TerraPower breaks ground on Ac-225 isotope facility
TerraPower Isotopes has broken ground on a $450M actinium-225 manufacturing facility in Philadelphia. The company said the site will increase global Ac-225 production capacity 20-fold.